SCHEMBL20134804

SCHEMBL20134804

Cc1cc(C2CC2)cnc1N1CCN(C(=O)c2ccc(C3(C4CCOCC4)NC(=O)NC3=O)cc2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.36
ADAMTS5 Q9UNA0 2/20 0.36
SLC6A7 Q99884 1/20 0.34
ABL1 P00519 2/20 0.34
BCR P11274 1/20 0.34
ALDH1A1 P00352 2/20 0.34
EGLN1 Q9GZT9 1/20 0.34
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
THRB P10828 1/20 0.33
FASN P49327 1/20 0.33
REV1 Q9UBZ9 1/20 0.33
MGLL Q99685 1/20 0.33
PDE2A O00408 1/20 0.33
MMP2 P08253 1/20 0.33
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33
OPRM1 P35372 1/20 0.32
OPRL1 P41146 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688558 1.00 ADAM17 (0.36) ADAM17ADAMTS5SLC6A7ABL1BCR
SCHEMBL29688969 0.94 SLC6A7 (0.37) ADAM17ADAMTS5SLC6A7ALDH1A1EGLN1
SCHEMBL20135138 0.94 SLC6A7 (0.37) ADAM17ADAMTS5SLC6A7ALDH1A1EGLN1
SCHEMBL20134916 0.93 SLC6A7 (0.38) ADAM17ADAMTS5SLC6A7ALDH1A1EGLN1
SCHEMBL29688813 0.93 SLC6A7 (0.38) ADAM17ADAMTS5SLC6A7ALDH1A1EGLN1
SCHEMBL29688853 0.91 ADAM17 (0.37) ADAM17ADAMTS5ABL1BCRALDH1A1
SCHEMBL20135058 0.91 ADAM17 (0.37) ADAM17ADAMTS5ABL1BCRALDH1A1
SCHEMBL20134997 0.85 ADAMTS5 (0.38) ADAM17ADAMTS5ABL1BCRALDH1A1
SCHEMBL20134934 0.85 SLC6A7 (0.38) ADAM17ADAMTS5SLC6A7ALDH1A1EGLN1
SCHEMBL20134930 0.85 SLC6A7 (0.38) ADAM17ADAMTS5SLC6A7ALDH1A1EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US claimed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US claimed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP claimed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ADAM17 36/4885ADAMTS5 23/4885SLC6A7 3698/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ADAM17 39/4885ADAMTS5 25/4885SLC6A7 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.